NewcelX Ltd.
NCELHealthcare|Biotechnology|CH
$2.72
-0.17 (-5.73%)
DCF Value
$0.18
Graham Number
$2.39
Cash / Share
$0.12
Analyst Consensus
Buy2 analysts
Strong Buy
0
Buy
2
Hold
0
Sell
0
Strong Sell
0
Rating Trend
Jun 24
0 buy · 1 hold · 0 sell
Jul 24
0 buy · 1 hold · 0 sell
Aug 24
0 buy · 1 hold · 0 sell
Sep 24
0 buy · 1 hold · 0 sell
Oct 24
0 buy · 1 hold · 0 sell
Nov 24
0 buy · 1 hold · 0 sell
Jul 26
1 buy · 0 hold · 0 sell
Aug 26
1 buy · 0 hold · 0 sell
Sep 26
1 buy · 0 hold · 0 sell
Oct 26
1 buy · 0 hold · 0 sell
Earnings History
Next report: Mar 3, 2027 · EPS est. $-0.65| Report Date | EPS Actual | EPS Est. | Revenue Actual | Revenue Est. |
|---|---|---|---|---|
| Sep 2, 2026 | $-0.53 | $-0.53 | — | — |
| Feb 25, 2026 | $1.29 | — | — | — |
| Oct 6, 2025 | $-10.50 | — | — | — |
| May 16, 2025 | $-26.30 | — | — | — |
| Oct 18, 2024 | $-1.94 | — | — | — |
| May 15, 2024 | $-1.40 | $-84.00 | — | — |
| Dec 6, 2023 | $-68.00 | $-68.00 | — | — |
| May 5, 2023 | $-2.90 | $-120.00 | — | — |
News
NewcelX Enters into Binding Term Sheet to Divest Legacy Mazindol Portfolio (CVR), Providing for Upfront Cash, Equity Ownership and Up to $55 Million in Potential Milestone Payments
Transaction provides $500,000 upfront of which $30,000 is in cash and the remainder in shares , representing a 9.4% equity stake in REA Holdings, alongside potential worldwide royalties of up to 8%
Nov 4, 2026globenewswire.com
NewCelX Management to Attend Breakthrough T1D Congress in Philadelphia, Advancing Its Mission to Develop a Cure for Type 1 Diabetes
ZURICH, Sept. 28, 2026 (GLOBE NEWSWIRE) -- NewcelX Ltd.
Sep 28, 2026globenewswire.com